Ankylosing Spondylitis Market Trends That Will Shape the Next Decade: Insights from Advancements In Therapeutic Options Drive Growth In The Ankylosing Spondylitis Market

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Ankylosing Spondylitis Market Size By 2025?
The valuation of the ankylosing spondylitis sector has experienced robust expansion over the past few years, projected to advance from a figure of $5.9 billion in the year 2024 up to $6.34 billion by 2025, reflecting a compound annual growth rate of 7.5%; this upward trajectory during the historical span is largely traceable to the identification of hla-b27, the creation of sophisticated biologic therapies, improvements in handling discomfort, heightened patient knowledge and support systems, alongside the utilization of NSAIDS and disease-modifying pharmaceuticals.

How Big Is the Ankylosing Spondylitis Market Size Expected to Grow by 2029?
Anticipating substantial expansion, the valuation of the ankylosing spondylitis market is projected to reach $8.68 billion by 2029, marking a significant upward trajectory evidenced by an 8.2% compound annual growth rate over the ensuing years; this robust expansion is fundamentally driven by advancements such as the adoption of personalized treatment strategies, ongoing innovation in novel biologic agents, enhanced early detection and screening protocols, growing focus on lifestyle and dietary control, and the increasing integration of telemedicine alongside remote patient surveillance.Key movements expected to shape this market throughout the projection timeframe encompass the introduction of biosimilar alternatives, the maturation of highly specific pain management treatments, heightened importance placed on patient-reported outcome measures, expansion of peer support initiatives, and continued investigation into regenerative medical solutions.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Key Market Drivers Powering Ankylosing Spondylitis Market Expansion and Growth?
Anticipated expansion in the segment dedicated to ankylosing spondylitis treatment is primarily fueled by the escalating proportion of elderly individuals within the populace. This demographic trend signifies a growing share of older adults resulting from shifts in population age composition, consequently boosting the count of those exceeding sixty years old. Therapies and pharmaceuticals employed for ankylosing spondylitis offer significant benefits to elderly patients suffering from this ailment by enhancing their ability to move and controlling discomfort. As a concrete example illustrating this trend, data released in January 2023 by the United Nations Department of Economic and Social Affairs (UN DESA), which functions as a division of the UN Secretariat, projects that the worldwide count of persons aged 65 and above will more than double, rising from 761 million in 2021 to reach 1.6 billion by the year 2050, thus establishing the burgeoning senior demographic as a key impetus behind the expansion of the ankylosing spondylitis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Ankylosing Spondylitis Market?
A significant shift toward enhanced therapeutic modalities is currently becoming a prominent development within the ankylosing spondylitis arena, pushing organizations active in this sector to evolve their offerings to maintain competitive advantage. As an illustration of this progress, the US biopharmaceutical entity, AbbVie Inc., secured authorization from the U.S. Food and Drug Administration (FDA) in April 2022 for RINVOQ, intended for adult individuals dealing with active ankylosing spondylitis (AS), thereby introducing an alternative, orally administered therapy for those previously unresponsive to TNF inhibitors; this option demonstrated notable enhancements in indicators like physical capability and discomfort, and its quick effectiveness alongside a substantiated safety record from clinical testing solidifies its role as a crucial step forward, broadening the spectrum of care accessible to those affected by this persistent inflammatory ailment.

What Are the Emerging Segments in the Ankylosing Spondylitis Market?
The ankylosing spondylitismarket covered in this report is segmented -

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Disease-Modifying Anti-Rheumatic Drugs (DMARDS); Biological Therapies; Steroids; Physical Therapies; Surgery
2) By Molecule: Biologics; Biosimilar; Small Molecules
3) By Route Of Administration: Parenteral; Oral; Other Routes
4) By Application: Juveniles; Adults
5) By End User: Hospitals; Clinics; Research Laboratories; Other End Users

Subsegments:
1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs; Prescription NSAIDs
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs; Targeted DMARDs
3) By Biological Therapies: TNF Inhibitors; IL-17 Inhibitors
4) By Steroids: Oral Steroids; Injectable Steroids
5) By Physical Therapies: Physiotherapy; Exercise Programs
6) By Surgery: Joint Replacement Surgery; Spinal Surgery

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11962&type=smp

Who Are the Global Leaders in the Ankylosing Spondylitis Market?
Major companies operating in the ankylosing spondylitis market include Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Cedars-Sinai, Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., UCSF Health, Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Which are the Top Profitable Regional Markets for the Ankylosing Spondylitis Industry?
North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11962

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.